Authors
Latest:
Dr Nguyen on the Role of Concurrent Chemotherapy With TMT in MIBCAnthony T. Nguyen, MD, PhD, discusses the role of concurrent chemotherapy with trimodal therapy in patients with muscle-invasive bladder cancer.
Latest:
Dr Mukhtar on Recurrence Risk in Invasive Lobular CarcinomaRita Mukhtar, MD, discusses the risk of disease recurrence in patients with invasive lobular carcinoma.
Latest:
Dr Patel on the Utility of Orca-T in Hematologic MalignanciesSagar Patel, MD, discusses the utility of the Orca-T platform in patients with hematologic malignancies, highlighting the platform's safety.
Latest:
Dr. Moroney on the Evaluation of COM701 Plus BMS-986207 and Nivolumab in Ovarian CancerJohn Moroney, MD, discusses the evaluation of COM701 plus BMS-986207 and nivolumab in platinum-resistant ovarian cancer.
Latest:
Dr. Saltman on the Use of the DetermaIO Assay to Inform Immunotherapy Use in Advanced-Stage NSCLCDavid L. Saltman, MD, PhD, discusses the use of the 27-gene Determa immuno-oncology assay to inform use of single-agent immunotherapy in patients with advanced-stage non–small cell lung cancer.
Latest:
Dr. Scott on the Incorporation of GARD-Based Radiotherapy Dosing in OncologyJacob G. Scott, MD, DPhil, discusses the incorporation of genomic-adjusted radiation dose–based radiotherapy dosing in oncology.
Latest:
Dr Lai on NCCN Guideline Updates in AML Maintenance TherapyCatherine E. Lai, MD, MPH, discusses NCCN guideline updates regarding AML maintenance therapy, sharing how these updates influence treatment decisions.
Latest:
Dr. Vasileiou on the Potential Role of ALVR109 for the Treatment of COVID-19Spyridoula Vasileiou, PhD, discusses the potential role of ALVR109, a SARS-CoV-2 virus–specific T-cell therapy, for the treatment of coronavirus disease 2019.
Latest:
Dr Haight on Predictors of Treatment Toxicity in Gynecologic MalignanciesPaulina J Haight, MD, discusses predictors of toxicity and treatment response with lenvatinib and pembrolizumab in patients with gynecologic malignancies.
Latest:
Dr Vokes on Targeting HER3 in NSCLCNatalie Vokes, MD, discusses emerging biomarkers in non–small cell lung cancer, specifically highlighting the promise of HER3-targeted therapy.
Latest:
Dr. Chmura on the Management of Oligometastatic Breast CancerSteven J. Chmura, MD, PhD, discusses the current management strategies for oligometastatic breast cancer.
Latest:
Well-Differentiated Systemic Mastocytosis vs Chronic Mast Cell LeukemiaThe panel of experts discuss the clinical differences between well-differentiated systemic mastocytosis and chronic mast cell leukemia.
Latest:
Community-Based Oncology Practices Adapt to Uncertainty of PandemicThe impact of COVID-19 has been felt deeply by community-based oncologists.
Latest:
Dr Sundaresan on Reasons Why Patients With Pancreatic Cancer May Decline TreatmentTilak Sundaresan, MD, on results of a retrospective study of reasons why patients with pancreatic cancer decline treatment.
Latest:
Dr. Hinrichs on Unmet Needs with Cellular Therapy in Metastatic Epithelial CancerChristian S. Hinrichs, MD, discusses unmet needs with cellular therapies in metastatic epithelial cancer.
Latest:
Dr. Schiffer on Factors to Consider for TKI Discontinuation in CMLCharles Schiffer, MD, discusses factors to consider for TKI discontinuation in chronic myeloid leukemia.
Latest:
Dr. He Discusses Discovery of Cancer-Inducing Mutation in Thymic Epithelial CellsYongfeng He, PhD, discusses the identification of the GTF2I L424H mutation in mouse models of thymic cancer.
Latest:
Considerations When Treating Patients With Metastatic Renal Cell CarcinomaSimilar to first-line therapy choices, particular treatment factors, including type and duration of response to prior therapy, pace of disease progression, and toxicities associated with first-line treatment, are all practical considerations that help guide therapy selection in metastatic renal cell carcinoma.
Latest:
Dr. Shroff on Unmet Needs in Advanced Biliary Tract CancerRachna T. Shroff, MD, MS, discusses unmet needs in advanced biliary tract cancer.
Latest:
Bredel Findings Address Understanding of Diffuse GliomasA groundbreaking discovery by Markus Bredel, MD, PhD, and colleagues not only marks a significant milestone in our understanding of diffuse gliomas but also paves the way for improved predictions of disease outcomes and the development of targeted treatment approaches.
Latest:
Obecabtagene Autoleucel (obe-cel, AUTO1) for Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Pooled Analysis of the Ongoing FELIX Phase Ib/II StudyClaire Roddie, MD, PhD, presents data from the pooled analysis of the ongoing FELIX phase Ib/II study investigating obecabtagene autoleucel in patients with relapsed/refractory adult B-cell acute lymphoblastic leukemia.
Latest:
Dr Anderson on Novel and Emerging Therapeutics in HR+ Breast CancerKaren S. Anderson, MD, PhD, discusses novel and emerging therapies, as well as potential future targets, for the treatment of patients with hormone receptor–positive breast cancer.
Latest:
Long-Term Data Solidify the Role of Zanubrutinib in R/R CLL: With Alexey Danilov, MD, PhD; and Nicole Lamanna, MDDrs Danilov and Lamanna discuss key efficacy data from the final comparative analysis of the ALPINE trial of zanubrutinib in relapsed/refractory CLL.
Latest:
Dr Aerts on the Rationale for the DENIM Trial in MesotheliomaJoachim G. J. V. Aerts, MD, PhD, discusses the rationale for conducting the phase 3 DENIM trial in patients with mesothelioma, highlighting the importance of focusing investigational efforts onto the dendritic cells.
Latest:
Illumination of Immune Checkpoint LAG3 ‘Black Box’ Could Yield New Cancer and Autoimmune TherapiesA new study pinpoints how LAG3 modulates T cell activity, providing important insights for development of other LAG3-blocking therapies for cancer and autoimmune disorders.
Latest:
Dr Schrag on Neoadjuvant Chemotherapy and Selective Chemoradiation in Locally Advanced Rectal CancerDeb Schrag, MD, MPH, discusses findings from the phase 2/3 PROSPECT trial in patients with rectal cancer.
Latest:
MET Inhibitors in NSCLC: Toxicity ManagementDrs Joshua M. Bauml and Benjamin Levy highlight more common adverse events associated with MET inhibitors used to treat MET exon 14 skipping mutations in non–small cell lung cancer and share strategies to help manage patients on therapy.
Latest:
Dr Grimm on the Rationale for Conducting a Post-Hoc Analysis of ARASENS in mHSPCMarc-Oliver Grimm, MD, discusses a post-hoc analysis of the ARASENS trial in metastatic hormone-sensitive prostate cancer.
Latest:
Dr. Lee on the Results of the REACH3 Trial in Chronic GVHDStephanie J. Lee, MD, MPH, discusses the results of the phase 3 REACH3 trial in chronic graft-vs-host disease.
